OSMCX | VIISX | OSMCX / VIISX | |
Total Expense Ratio | 2.13 | 1.18 | 181% |
Annual Report Gross Expense Ratio | 2.13 | 1.18 | 181% |
Fund Existence | 27 years | 13 years | - |
Gain YTD | -1.037 | 3.428 | -30% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000 | 100000 | 1% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 3.24B | 929M | 348% |
Annual Yield % from dividends | 0.53 | 1.81 | 29% |
Returns for 1 year | -15.14 | 9.55 | -159% |
Returns for 3 years | -21.60 | 11.03 | -196% |
Returns for 5 years | -13.61 | 37.49 | -36% |
Returns for 10 years | -7.90 | 71.46 | -11% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
EET | 48.22 | 2.74 | +6.03% |
ProShares Ultra MSCI Emerging Markets | |||
ESGE | 33.41 | 1.00 | +3.09% |
iShares ESG Aware MSCI EM ETF | |||
PBE | 58.23 | 1.65 | +2.91% |
Invesco Biotechnology & Genome ETF | |||
EUSC | 39.69 | 0.53 | +1.35% |
WisdomTree Europe Hedged SmallCap Eq ETF | |||
JVAL | 38.34 | 0.48 | +1.27% |
JPMorgan US Value Factor ETF |